Summary of Certara FY Conference Call (March 10, 2026) Company Overview - **Company**: Certara (NasdaqGS:CERT) - **Industry**: Life Science Tools and Diagnostics Key Financial Performance - **Revenue**: Organic software revenue for FY 2025 was 7%, within the guidance range of 6%-8% [5] - **EBITDA Margin**: Achieved 32%, exceeding the guidance of 30%-32% [5] - **Bookings**: Mixed performance in Q4; December saw a strong 17% increase in services bookings [6][7] - **Software Bookings**: Trailing twelve-month organic software bookings were only 1%, indicating a decline year-on-year in Q4 [7][8] Market Dynamics - **Customer Behavior**: Notable reduction in seat licenses from tier one customers due to headcount reductions in Big Pharma [14][15] - **Study Counts**: Decreased clinical trial starts 18-24 months prior affected software bookings, particularly for the Pinnacle 21 platform [15][16] - **Seasonality**: Q4 showed strong discretionary spending, but services bookings remain lumpy historically [6][7] 2026 Guidance and Expectations - **Revenue Growth**: Expected to be flat to up 4% for 2026, with Q1 anticipated to be on the lower end of the guidance range [8][20] - **New Product Launches**: Three new software products launched in Q4, including Certara IQ for QSP and Phoenix Cloud, expected to drive growth [22][30] Product Development and AI Integration - **Certara IQ**: AI-enabled software for quantitative systems pharmacology (QSP), aimed at enhancing internal project throughput and customer sales [28][30] - **Phoenix Cloud**: Cloud version of the Phoenix platform, designed to transition customers from desktop to cloud, with positive initial reception [32][35] - **AI as Competitive Advantage**: Integration of AI technology from Vyasa is seen as a unique opportunity to enhance software offerings and maintain customer reliance [42][44] Regulatory Services and Strategic Evaluation - **Regulatory Writing Business**: High profit margins (20%-30%) but facing revenue declines; under evaluation for potential sale or retention [58][61] - **CEO's Focus**: New CEO Jon Resnick is assessing the regulatory business's status and its impact on shareholder value [55][57] Investment and Growth Strategy - **Customer-Centric Approach**: Emphasis on unifying software and services to better meet customer needs and enhance value proposition [72][73] - **Rule of Forty**: Company aims to align with the rule of forty, currently slightly below due to investments impacting margins [79][80] - **Cost Management**: Identified $10 million in cost avoidance opportunities while maintaining disciplined spending [83][85] Conclusion - Certara is navigating a transitional phase with mixed financial performance, focusing on new product launches and AI integration to drive future growth while evaluating its regulatory services segment for strategic decisions.